Sender Gary 4

What Happened

• Gary, a director of Harmony Biosciences Holdings, Inc., was granted 21,872 derivative securities on May 14, 2026. The Form 4 reports the acquisition as a grant/award (derivative) with a reported price of $0.00 and $0 cash paid at the time of grant. This is a compensation award, not an open-market buy or sale.

Key Details

• Transaction date: 2026-05-14; filing date: 2026-05-18 (filed within the normal two-business-day window).
• Reported price at grant: $0.00; total reported cash exchanged at grant: $0.
• Shares acquired: 21,872 derivative shares (reported as a stock option award).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: the award is described as a stock option that vests in full on the earlier of (i) May 14, 2027 or (ii) the date of the next annual meeting following the grant date, subject to continued service (see F1).
• No 10b5-1, tax-withholding sale, or immediate sale indicated.

Context

• This transaction is a compensation grant (a derivative option award) that vests in the future; it does not involve an immediate purchase or sale of shares. Such grants are common for directors and are intended as long-term compensation rather than a market-timing signal.